Cord blood-derived CD133+ cells improve cardiac function after myocardial infarction

Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence. HUCB-derived EPCs could be an alternative to rescue impaired stem cell function in the sick and elderly.

The results, which appear in the January 2010 issue of Experimental Biology and Medicine, show that expanded cells ex vivo exhibited increased expression of mature endothelial cells markers and formed tubule-like structures in vitro. Only the expanded cells expressed VEGF mRNA.

Cells were expanded up to 70-fold during 60 days of culture, and they retained their functional activity. A significant improvement was observed in left ventricular ejection fraction for purified and expanded cells. In summary, CD133+ cells were purified from HUCB, expanded in vitro without losing their biological activity, and both purified and expanded cells showed promising results for use in cellular cardiomyoplasty. However, further pre-clinical testing should be performed to determine whether expanded CD133+ cells have any clinical advantages over purified CD133+ cells.

Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said “This study suggests that the use of human umbilical cord blood-derived purified and expanded CD133+ cells may show promise for use in cellular cardiomyoplasty. This finding needs subsequent pre-clinical testing but may prove to be very important in future treatments”.

Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit www.sebm.org. If you are interested in publishing in the journal please visit www.ebmonline.org.